ASCO Gastrointestinal Cancers Symposium

Bild/Picture ®Thomas Ferber/Oncoletter

  • Oral Abstract Session A: Cancers of the Esophagus and Stomach
  • Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
  • Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

Oral Abstract Session A: Cancers of the Esophagus and Stomach

Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.

Francesca Battaglin, Andrew Elliott, Jian Zhang, et al.

The study identified candidate recurrent peptides with high HLA-binding affinity and an association with a positive TIS signature in both MSI and MSS tumors. This points to the importance of recurrent neoantigens as potential cancer immunotherapy targets.

 

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Jean-Philippe Metges, Ken Kato, Jong-Mu Sun, et al.

This study demonstrates: Pembrolizumab plus chemotherapy continued to show a significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy alone with a manageable safety profile. The study recommends first-line treatment with pembrolizumab plus chemotherapy as the new standard of care in untreated, advanced esophageal and EGJ cancer. More info at NCT03189719.

 

Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649.

Kohei Shitara, Yelena Y. Janjigian, Markus H. Moehler, et al.

The continued clinically meaningful efficacy and acceptable safety profile support the use of nivolumab plus chemotherapy as standard first-line therapy in previously untreated patients with advanced advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC). More info at: NCT02872116.

 

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

Ken Kato, Yoshinori Ito, Hiroyuki Daiko, et al.

Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) improved overall survival over cisplatin and 5-fluorouracil for locally advanced esophageal cell squamous carcinoma. The toxicity profile proved to be manageable. For the study authors, DCF means the new standard for the neoadjuvant treatment of ESCC.

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial.

Zhenwei Peng, Wenzhe Fan, Bowen Zhu, Jiaping Li, Ming Kuang

Lenvatinib along with transarterial chemoembolization may improve clinical outcomes. For the study authors, this could be the new first-line treatment for advanced hepatocellular carcinoma. More info: NCT03905967.

 

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do-Youn Oh, Aiwu Ruth He, Shukui Qin, et al.

The study results with a significantly better overall survival and disease-free survival indicate that durvalumab + gemcitabine/cisplatin could be a new first-line standard of care for advanced biliary tract cancer. More info: NCT03875235.

 

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou-Alfa, Stephen Lam Chan, Masatoshi Kudo, et al.

Durvalumab was non-inferior to sorafenib. The safety of the treatment is rated as favorable by the authors. The combination of a single initial dose of tremelimumab(T) plus durvalumab (D) in Single T Regular Interval D (STRIDE) resulted in superior efficacy compared to sorafenib. The authors assess the risk-benefit profile as favorable and recommend STRIDE as a new systemic first-line therapy standard for unresectable hepatocellular carcinoma (uHCC). More info: NCT03298451.

 

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

Pascal Hammel, Iman El-Hariry, Teresa Macarulla, et al.

The addition of eryaspase demonstrated a well-tolerated profile and an encouraging survival benefit in the irinotecan/5FU subgroup, but the primary endpoint of improved overall survival was missed. More info: NCT03665441.

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.

Claire Gallois, Qian Shi, Jeffrey P. Meyers, et al.

Oxaliplatin-based adjuvant chemotherapy for six months in stage III colon cancer resulted in a decrease in disease-free and overall survival when treatment was stopped early. Discontinuation of oxaliplatin early did not result in significantly worse outcomes. If significant neurotoxicity occurs during a 6-month program, the available data advise against continuing oxaliplatin beyond 75% of planned cycles of adjuvant chemotherapy. The study continues to favor fluoropyrimidines as the cornerstone of adjuvant chemotherapy for localized colon cancer.

 

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.

Heinz-Josef Lenz, Aparna Raj Parikh, David R. Spigel, et al.

Despite not meeting the primary endpoint of progression-free survival (PFS), NIVOLUMAB plus standard of care showed higher PFS rates after 12 months with acceptable safety. A higher response rate and more durable responses compared to standard of care in first-line metastatic colorectal cancer were also observed. More info: NCT03414983.

 

A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).

Tetsuya Hamaguchi, Atsuo Takashima, Junki Mizusawa, et al.

With or without the addition of oxaliplatin, there is no difference in survival benefit. OX is not recommended as initial therapy for elderly patients with metastatic colorectal cancer. More information: UMIN000008866.

 

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.

Masahito Kotaka, Hiromichi Shirasu, Jun Watanabe, et al.

The authors note the association between ctDNA dynamics and improved clinical outcomes in MRD-positive patients: Stratification of postoperative treatment decisions using the assay is able to identify patients who are likely to benefit from adjuvant chemotherapy at all stages, including pStage II. More information: jRCT1031200006.

 

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close